Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dementia Severe Clear all

Conditions: Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions: Dexmedetomidine, Lorazepam 2 MG/ML; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Alzheimer Disease
Interventions: Bryostatin 1, Placebo; Drug · Other
Lead sponsor: Neurotrope Bioscience, Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 19
States / cities: Colton, California • San Diego, California • Atlantis, Florida + 16 more

Conditions: Alzheimer Disease, Dementia
Interventions: Faith-based Home Activity Toolbox (Faith-HAT); Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Fairburn, Georgia

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: alemtuzumab, methylprednisolone, prednisone, flow cytometry, immunologic technique, pharmacological study; Biological · Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions: Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline; Drug
Lead sponsor: Centre for Addiction and Mental Health; Other
Eligibility: 60 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • St Louis, Missouri • New York, New York

Conditions: Alzheimer's Disease
Interventions: memantine HCl; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 50 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 9
States / cities: San Francisco, California • Westminster, California • New Haven, Connecticut + 6 more

Conditions: Problem Behavior, Aggression
Interventions: Response Blocking; Behavioral
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Autism Spectrum Disorder, Challenging Behaviour, Aggression, Severe Disruptive Behaviour Disorders, Self-injury
Interventions: Propranolol, Placebo; Drug
Lead sponsor: Jeremy Veenstra-vanderweele; Other
Eligibility: 12 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Staten Island, New York • White Plains, New York

Conditions: Autism Spectrum Disorder, Developmental Disability, Aggression, Self-Injurious Behavior, Challenging Behavior
Interventions: Propranolol; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 12 Years to 30 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Alzheimer's Disease
Interventions: Group 1 ELND005, Group 2 ELND005; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 50 Years to 95 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encino, California + 35 more

Conditions: Sepsis, Respiratory Failure, Agitation
Interventions: Propofol, Dexmedetomidine, Fentanyl; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Agitation, Excited Delirium, Pain
Interventions: Not listed
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Alzheimer Disease
Interventions: Bryostatin, Placebo; Drug · Other
Lead sponsor: Neurotrope Bioscience, Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 28
States / cities: Fresno, California • Los Alamitos, California • Santa Ana, California + 23 more

Conditions: Dementia, Dementia Alzheimers, Neuro-Degenerative Disease, Dementia of Alzheimer Type, Dementia Severe
Interventions: Not listed
Lead sponsor: Karen Roberto; Other
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Parkinson's Disease Dementia
Interventions: Rivastigmine capsule, Rivastigmine transdermal patch; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more

Conditions: Aggression, Self-Injurious Behavior
Interventions: Functional Communication Training; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 3 Years to 18 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Alzheimer's Disease
Interventions: Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 1,467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Hickory, North Carolina

Conditions: Depression NOS, Major Depressive Disorder, Anxiety NOS
Interventions: Kirtan Kriya meditation, Relaxation; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 45 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Alzheimer's Disease
Interventions: Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 50 Years and older
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 93
States / cities: Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more

Conditions: Alzheimer Disease, Dementia, Major Neurocognitive Disorder With Aggressive Behavior
Interventions: THC-free CBD Oil, Placebo; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 50 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Dementia of the Alzheimer's Type
Interventions: memantine ER, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 50 Years and older
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 38
States / cities: Phoenix, Arizona • Costa Mesa, California • Fresno, California + 34 more

Conditions: Alzheimer's Disease, Dementia, Behavioral Symptoms
Interventions: Divalproex ER, Quetiapine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 55 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Dementia, Postoperative Delirium (POD), Postoperative Neurocognitive Disorder, Major Adverse Cardiac and Cerebrovascular Events, Perioperative Complications, Postoperative Cognitive Decline
Interventions: Personalized CPC Prehabilitation, Cognitive Training, Meditation, Daily Exercise, Enhanced Social Support, Proactive Bundle Interventions, Pre-operative Standard of Care, Intra-operative Standard of Care; Other · Behavioral · Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Pittsburgh, Pennsylvania

Conditions: Mentalizing Imagery Therapy, Relaxation Recording
Interventions: Mentalizing Imagery Therapy, Relaxation cd; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 45 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

Bryostatin Treatment of Moderately Severe Alzheimer's Disease

Faith-Based Toolbox for African Americans With Dementia

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease

Identifying Precursors to Severe Problem Behavior

Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism

Propranolol for Challenging Behaviors in Autism

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure

Stress Biomarkers Among Patients Undergoing Treatment for Excited Delirium and Severe Pain in the Emergency Department

A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine

Persons With Dementia and Their Extended Family Caregivers

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Meditation to Reduce Caregiver Stress

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease

A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

Prediction and Prevention of Postoperative Mortality and Morbidity

Meditation for Dementia Caregivers Major Depressive Disorder in Family Dementia Caregivers